Calquence (acalabrutinib)

Numéro de dossier de l’APP: 21416
État des négociations:
Concluded with an LOI
Indication(s):
Chronic Lymphocytic Leukemia (CLL) (previously untreated): With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate
Promoteur/fabricant:
ASTRAZENECA CANADA INC
Numéro de projet de l’ACMTS:
PC0210-000
Lettre-contrat de l’APP:
Conclusion du processus de négociation: